Parion Sciences is a development stage company dedicated to research, development, and commercialization of therapies to restore the innate mucosal surface defense of the lung.
Parion’s science driven technologies target respiratory diseases that are caused by defective mucosal host defense
- Parion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The Lancet Respiratory Medicine
- Parion Sciences Receives Positive Opinion from EMA Paediatric Committee on the Paediatric Investigation Plan for Idrevloride Inhalation Solution for Treatment of Primary Ciliary Dyskinesia
- Parion Sciences P‐1037 Inhalation Solution receives Orphan Drug Designation from the EMA for the Treatment of Primary Ciliary Dyskinesia